Patents by Inventor Timothy Z. Vitalis

Timothy Z. Vitalis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • P97 fusion proteins
    Patent number: 11643454
    Abstract: Provided are p97 (melanotransferrin)-trastuzumab fusion proteins and related methods of use thereof, for instance, to facilitate delivery of trastuzumab across the blood-brain barrier (BBB) and/or improve tissue penetration of the antibody in CNS and peripheral tissues, and thereby treat and/or diagnose HER2-positive cancers, including those of the central nervous system (CNS).
    Type: Grant
    Filed: February 10, 2019
    Date of Patent: May 9, 2023
    Assignee: BIOASIS TECHNOLOGIES, INC.
    Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
  • P97-IDS fusion proteins
    Patent number: 11124781
    Abstract: Provided are fusion proteins between p97 (melanotransferrin) and iduronate-2-sulfatase (IDS), and related compositions and methods of use thereof, for instance, to facilitate delivery of IDS across the blood-brain barrier (BBB) and/or improve its tissue penetration in CNS and/or peripheral tissues, and thereby treat and/or diagnose Hunter Syndrome (Mucopolysaccharidosis type II; MPS II) and related lysosomal storage disorders, including those having a central nervous system (CNS) component.
    Type: Grant
    Filed: June 22, 2019
    Date of Patent: September 21, 2021
    Assignee: Bioasis Technologies, Inc.
    Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
  • Dephosphorylated lysosomal storage disease proteins and methods of use thereof
    Patent number: 11034943
    Abstract: Provided are substantially dephosphorylated forms of lysosomal storage disease (LSD) proteins, including dephosphorylated forms of iduronate-2-sulfatase (IDS, or I2D) and iduronidase (IDU), having increased ability to traverse or penetrate the blood brain barrier (BBB) relative to phosphorylated forms of the protein, and p97 conjugates thereof. Also provided are compositions comprising such dephosphorylated LSD proteins and p97 conjugates, and methods of use thereof, for instance, to treat any one or more lysosomal storage diseases, such as Hunter Syndrome (or MPS Type II).
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: June 15, 2021
    Assignee: biOasis Technologies, Inc.
    Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
  • FRAGMENTS OF P97 AND USES THEREOF
    Publication number: 20200376092
    Abstract: Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising the p97 fragments, and related methods of use thereof, for instance, to facilitate the delivery of therapeutic or diagnostic agents across the BBB and into the central nervous system.
    Type: Application
    Filed: August 13, 2020
    Publication date: December 3, 2020
    Applicant: Bioasis Technologies, Inc.
    Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
  • Fragments of P97 and uses thereof
    Patent number: 10772939
    Abstract: Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising the p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the BBB.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: September 15, 2020
    Assignee: Bioasis Technologies, Inc.
    Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
  • P97-IDS FUSION PROTEINS
    Publication number: 20200270590
    Abstract: Provided are fusion proteins between p97 (melanotransferrin) and iduronate-2-sulfatase (IDS), and related compositions and methods of use thereof, for instance, to facilitate delivery of IDS across the blood-brain barrier (BBB) and/or improve its tissue penetration in CNS and/or peripheral tissues, and thereby treat and/or diagnose Hunter Syndrome (Mucopolysaccharidosis type II; MPS II) and related lysosomal storage disorders, including those having a central nervous system (CNS) component.
    Type: Application
    Filed: June 22, 2019
    Publication date: August 27, 2020
    Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
  • P97 FUSION PROTEINS
    Publication number: 20190315837
    Abstract: Provided are p97 (melanotransferrin)-trastuzumab fusion proteins and related methods of use thereof, for instance, to facilitate delivery of trastuzumab across the blood-brain barrier (BBB) and/or improve tissue penetration of the antibody in CNS and peripheral tissues, and thereby treat and/or diagnose HER2-positive cancers, including those of the central nervous system (CNS).
    Type: Application
    Filed: February 10, 2019
    Publication date: October 17, 2019
    Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
  • P97-IDS fusion proteins
    Patent number: 10392605
    Abstract: Provided are fusion proteins between p97 (melanotransferrin) and iduronate-2-sulfatase (IDS), and related compositions and methods of use thereof, for instance, to facilitate delivery of IDS across the blood-brain barrier (BBB) and/or improve its tissue penetration in CNS and/or peripheral tissues, and thereby treat and/or diagnose Hunter Syndrome (Mucopolysaccharidosis type II; MPS II) and related lysosomal storage disorders, including those having a central nervous system (CNS) component.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: August 27, 2019
    Assignee: Bioasis Technologies Inc.
    Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
  • FRAGMENTS OF P97 AND USES THEREOF
    Publication number: 20190008929
    Abstract: Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising said p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the BBB.
    Type: Application
    Filed: May 8, 2018
    Publication date: January 10, 2019
    Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
  • DEPHOSPHORYLATED LYSOSOMAL STORAGE DISEASE PROTEINS AND METHODS OF USE THEREOF
    Publication number: 20190002852
    Abstract: Provided are substantially dephosphorylated forms of lysosomal storage disease (LSD) proteins, including dephosphorylated forms of iduronate-2-sulfatase (IDS, or I2D) and iduronidase (IDU), having increased ability to traverse or penetrate the blood brain barrier (BBB) relative to phosphorylated forms of the protein, and p97 conjugates thereof. Also provided are compositions comprising such dephosphorylated LSD proteins and p97 conjugates, and methods of use thereof, for instance, to treat any one or more lysosomal storage diseases, such as Hunter Syndrome (or MPS Type II).
    Type: Application
    Filed: April 2, 2018
    Publication date: January 3, 2019
    Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
  • Fragments of P97 and uses thereof
    Patent number: 9993530
    Abstract: Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising the p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the BBB.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: June 12, 2018
    Assignee: Bioasis Technologies, Inc.
    Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
  • Dephosphorylated lysosomal storage disease proteins and methods of use thereof
    Patent number: 9932565
    Abstract: Provided are substantially dephosphorylated forms of lysosomal storage disease (LSD) proteins, including dephosphorylated forms of iduronate-2-sulfatase (IDS, or I2D) and iduronidase (IDU), having increased ability to traverse or penetrate the blood brain barrier (BBB) relative to phosphorylated forms of the protein, and p97 conjugates thereof. Also provided are compositions comprising such dephosphorylated LSD proteins and p97 conjugates, and methods of use thereof, for instance, to treat any one or more lysosomal storage diseases, such as Hunter Syndrome (or MPS Type II).
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: April 3, 2018
    Assignee: biOasis Technologies, Inc.
    Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
  • P97-antibody conjugates and methods of use
    Patent number: 9850472
    Abstract: The present invention provides p97-antibody conjugates and related compositions and methods, which may be used in any of a variety of therapeutic methods, including methods for the treatment of cancers such as Her2/neu-expressing and Her1/EGFR-expressing cancers.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: December 26, 2017
    Assignee: BIOASIS TECHNOLOGIES, INC.
    Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
  • P97-IDS FUSION PROTEINS
    Publication number: 20170204386
    Abstract: Provided are fusion proteins between p97 (melanotransferrin) and iduronate-2-sulfatase (IDS), and related compositions and methods of use thereof, for instance, to facilitate delivery of IDS across the blood-brain barrier (BBB) and/or improve its tissue penetration in CNS and/or peripheral tissues, and thereby treat and/or diagnose Hunter Syndrome (Mucopolysaccharidosis type II; MPS II) and related lysosomal storage disorders, including those having a central nervous system (CNS) component.
    Type: Application
    Filed: February 15, 2015
    Publication date: July 20, 2017
    Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
  • P97 FUSION PROTEINS
    Publication number: 20160347821
    Abstract: Provided are p97 (melanotransferrin)-trastuzumab fusion proteins and related methods of use thereof, for instance, to facilitate delivery of trastuzumab across the blood-brain barrier (BBB) and/or improve tissue penetration of the antibody in CNS and peripheral tissues, and thereby treat and/or diagnose HER2-positive cancers, including those of the central nervous system (CNS).
    Type: Application
    Filed: February 3, 2015
    Publication date: December 1, 2016
    Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
  • FRAGMENTS OF P97 AND USES THEREOF
    Publication number: 20160324937
    Abstract: Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising said p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the BBB.
    Type: Application
    Filed: May 12, 2016
    Publication date: November 10, 2016
    Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
  • Fragments of p97 and uses thereof
    Patent number: 9364567
    Abstract: Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising the p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the BBB.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: June 14, 2016
    Assignee: biOasis Technologies, Inc.
    Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
  • P97-ANTIBODY CONJUGATES AND METHODS OF USE
    Publication number: 20160053237
    Abstract: The present invention provides p97-antibody conjugates and related compositions and methods, which may be used in any of a variety of therapeutic methods, including methods for the treatment of cancers such as Her2/neu-expressing and Her1/EGFR-expressing cancers.
    Type: Application
    Filed: August 27, 2015
    Publication date: February 25, 2016
    Applicant: BIOASIS TECHNOLOGIES, INC.
    Inventors: Wilfred Jefferies, Timothy Z. Vitalis, Reinhard Gabathuler
  • P97-antibody conjugates and methods of use
    Patent number: 9150846
    Abstract: The present invention provides p97-antibody conjugates and related compositions and methods, which may be used in any of a variety of therapeutic methods, including methods for the treatment of cancers such as Her2/neu-expressing and Her1/EGFR-expressing cancers.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: October 6, 2015
    Assignee: biOasis Technologies, Inc.
    Inventors: Wilfred Jefferies, Timothy Z. Vitalis, Reinhard Gabathuler
  • FRAGMENTS OF P97 AND USES THEREOF
    Publication number: 20140322132
    Abstract: Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising said p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the BBB.
    Type: Application
    Filed: March 13, 2014
    Publication date: October 30, 2014
    Inventors: Timothy Z. Vitalis, Reinhard Gabathuler